Stock Screener
Stock Research
Delisted Stocks
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Long Term Debt 2010-2024 | IRWD

Ironwood Pharmaceuticals long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
  
Ironwood Pharmaceuticals Annual Long Term Debt
(Millions of US $)
2023 $498
2022 $396
2021 $
2020 $430
2019 $408
2018 $366
2017 $396
2016 $367
2015 $354
2014 $161
2013 $178
2012 $0
2011 $0
2010 $0
2009 $1
Ironwood Pharmaceuticals Quarterly Long Term Debt
(Millions of US $)
2024-03-31 $473
2023-12-31 $498
2023-09-30 $523
2023-06-30 $598
2023-03-31
2022-12-31 $396
2022-09-30 $396
2022-06-30 $395
2022-03-31 $395
2021-12-31
2021-09-30 $333
2021-06-30 $329
2021-03-31 $436
2020-12-31 $430
2020-09-30 $425
2020-06-30 $419
2020-03-31 $426
2019-12-31 $408
2019-09-30 $403
2019-06-30 $353
2019-03-31 $360
2018-12-31 $366
2018-09-30 $370
2018-06-30 $380
2018-03-31 $388
2017-12-31 $396
2017-09-30 $392
2017-06-30 $388
2017-03-31 $384
2016-12-31 $367
2016-09-30 $363
2016-06-30 $339
2016-03-31 $349
2015-12-31 $354
2015-09-30 $360
2015-06-30 $364
2015-03-31 $160
2014-12-31 $161
2014-09-30 $168
2014-06-30 $171
2014-03-31 $173
2013-12-31 $178
2013-09-30 $178
2013-06-30 $175
2013-03-31 $175
2012-12-31 $0
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $1
2011-03-31 $1
2010-12-31 $0
2010-09-30 $0
2010-06-30 $2
2010-03-31 $2
2009-12-31 $1
2009-09-30 $2
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $1.016B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $78.506B 31.92
Chugai Pharmaceutical (CHGCY) Japan $50.534B 22.59
Takeda Pharmaceutical (TAK) Japan $41.333B 8.37
Merck (MKGAF) Germany $23.559B 22.84
Astellas Pharma (ALPMY) Japan $17.572B 27.74
Sandoz Group AG (SDZNY) Switzerland $15.150B 0.00
Neurocrine Biosciences (NBIX) United States $14.032B 38.41
Shionogi (SGIOY) Japan $12.692B 11.03
United Therapeutics (UTHR) United States $12.262B 13.07
Catalent (CTLT) United States $9.948B 0.00
Cerevel Therapeutics Holdings (CERE) United States $7.588B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.651B 7.31
Revolution Medicines (RVMD) United States $6.562B 0.00
Orion OYJ (ORINY) Finland $5.645B 23.81
Ionis Pharmaceuticals (IONS) United States $5.547B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.396B 0.00
Madrigal Pharmaceuticals (MDGL) United States $5.009B 0.00
Crinetics Pharmaceuticals (CRNX) United States $3.986B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $3.122B 0.00
Summit Therapeutics (SMMT) United States $3.082B 0.00
Corcept Therapeutics (CORT) United States $2.980B 27.00
PTC Therapeutics (PTCT) United States $2.964B 0.00
Dyne Therapeutics (DYN) United States $2.755B 0.00
Indivior (INDV) United States $2.311B 10.95
Recursion Pharmaceuticals (RXRX) United States $2.196B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.053B 11.67
Catalyst Pharmaceuticals (CPRX) United States $1.906B 18.55
Evotec AG (EVO) Germany $1.832B 0.00
Fusion Pharmaceuticals (FUSN) Canada $1.830B 0.00
Ardelyx (ARDX) United States $1.820B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.762B 0.00
Taro Pharmaceutical Industries (TARO) Israel $1.608B 24.17
Avadel Pharmaceuticals (AVDL) Ireland $1.521B 0.00
Xencor (XNCR) United States $1.511B 0.00
Soleno Therapeutics (SLNO) United States $1.432B 0.00
Pacira BioSciences (PCRX) United States $1.430B 13.59
BioCryst Pharmaceuticals (BCRX) United States $1.374B 0.00
4D Molecular Therapeutics (FDMT) United States $1.352B 0.00
Collegium Pharmaceutical (COLL) United States $1.118B 6.69
Enliven Therapeutics (ELVN) United States $1.077B 0.00
Cronos Group (CRON) Canada $1.066B 0.00
Cassava Sciences (SAVA) United States $1.061B 0.00
Relay Therapeutics (RLAY) United States $1.000B 0.00
Ocular Therapeutix (OCUL) United States $0.929B 0.00
USANA Health Sciences (USNA) United States $0.925B 15.13
Centessa Pharmaceuticals (CNTA) United Kingdom $0.879B 0.00
ARS Pharmaceuticals (SPRY) United States $0.865B 0.00
ProKidney (PROK) United States $0.830B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.789B 0.00
Sage Therapeutics (SAGE) United States $0.728B 0.00
Lyell Immunopharma (LYEL) United States $0.704B 0.00
Silence Therapeutics (SLN) United Kingdom $0.695B 0.00
Calliditas Therapeutics AB (CALT) Sweden $0.647B 0.00
Harrow (HROW) United States $0.609B 0.00
Exscientia (EXAI) United Kingdom $0.598B 0.00
Savara (SVRA) United States $0.598B 0.00
Altimmune (ALT) United States $0.559B 0.00
Siga Technologies (SIGA) United States $0.532B 6.80
Heron Therapeutics (HRTX) United States $0.523B 0.00
OmniAb (OABI) United States $0.518B 0.00
Larimar Therapeutics (LRMR) United States $0.504B 0.00
Lexeo Therapeutics (LXEO) United States $0.499B 0.00
Bioventus (BVS) United States $0.499B 19.09
KalVista Pharmaceuticals (KALV) United States $0.493B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.480B 0.00
Verve Therapeutics (VERV) United States $0.470B 0.00
Korro Bio (KRRO) United States $0.466B 0.00
Esperion Therapeutics (ESPR) United States $0.451B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.437B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.384B 0.00
Organogenesis (ORGO) United States $0.374B 70.50
Fractyl Health (GUTS) United States $0.365B 0.00
Tourmaline Bio (TRML) United States $0.350B 0.00
Nektar Therapeutics (NKTR) United States $0.321B 0.00
Xeris Biopharma Holdings (XERS) United States $0.298B 0.00
Nanobiotix S.A (NBTX) France $0.293B 0.00
Nature's Sunshine Products (NATR) United States $0.292B 18.57
Aquestive Therapeutics (AQST) United States $0.287B 0.00
Black Diamond Therapeutics (BDTX) United States $0.284B 0.00
ESSA Pharma (EPIX) Canada $0.275B 0.00
Century Therapeutics (IPSC) United States $0.273B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.271B 0.00
Metagenomi (MGX) United States $0.269B 0.00
Foghorn Therapeutics (FHTX) United States $0.265B 0.00
Acrivon Therapeutics (ACRV) United States $0.265B 0.00
CytoDyn (CYDY) United States $0.238B 0.00
Akebia Therapeutics (AKBA) United States $0.231B 0.00
Aldeyra Therapeutics (ALDX) United States $0.230B 0.00
Pyxis Oncology (PYXS) United States $0.230B 0.00
Eliem Therapeutics (ELYM) United States $0.229B 0.00
Prelude Therapeutics (PRLD) United States $0.226B 0.00
Avita Medical (RCEL) United States $0.220B 0.00
Conduit Pharmaceuticals (CDT) United States $0.219B 0.00
Adherex Technologies (FENC) United States $0.196B 239.67
Zevra Therapeutics (ZVRA) United States $0.194B 0.00
Galectin Therapeutics (GALT) United States $0.193B 0.00
Profound Medical (PROF) Canada $0.193B 0.00
Achieve Life Sciences (ACHV) Canada $0.177B 0.00
Innate Pharma SA (IPHYF) France $0.176B 0.00
VAXART, INC (VXRT) United States $0.176B 0.00
Incannex Healthcare (IXHL) Australia $0.171B 0.00
MediWound (MDWD) Israel $0.167B 0.00
Telomir Pharmaceuticals (TELO) United States $0.166B 0.00
Elite Pharmaceuticals (ELTP) United States $0.164B 15.39
Rigel Pharmaceuticals (RIGL) United States $0.162B 0.00
Cardiol Therapeutics (CRDL) Canada $0.149B 0.00
Context Therapeutics (CNTX) United States $0.146B 0.00
Citius Pharmaceuticals (CTXR) United States $0.134B 0.00
OptiNose (OPTN) United States $0.131B 0.00
Karyopharm Therapeutics (KPTI) United States $0.131B 0.00
Regulus Therapeutics (RGLS) United States $0.126B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.124B 8.32
FibroGen (FGEN) United States $0.122B 0.00
PMV Pharmaceuticals (PMVP) United States $0.109B 0.00
Assertio Holdings (ASRT) United States $0.099B 4.52
ProPhase Labs (PRPH) United States $0.098B 0.00
Vivani Medical (VANI) United States $0.097B 0.00
SCYNEXIS (SCYX) United States $0.096B 1.35
Relmada Therapeutics (RLMD) United States $0.093B 0.00
AlloVir (ALVR) United States $0.090B 0.00
ARYA Sciences Acquisition Corp IV (ARYD) United States $0.086B 0.00
Aclaris Therapeutics (ACRS) United States $0.082B 0.00
Tempest Therapeutics (TPST) United States $0.073B 0.00
Journey Medical (DERM) United States $0.071B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.071B 0.00
Mural Oncology (MURA) Ireland $0.064B 0.00
Champions Oncology (CSBR) United States $0.064B 0.00
Protara Therapeutics (TARA) United States $0.062B 0.00
Reneo Pharmaceuticals (RPHM) United States $0.061B 0.00
Carisma Therapeutics (CARM) United States $0.059B 0.00
Nutriband (NTRB) United States $0.053B 0.00
Inotiv (NOTV) United States $0.053B 0.00
BioLineRx (BLRX) Israel $0.050B 0.00
CASI Pharmaceuticals (CASI) China $0.046B 0.00
Gain Therapeutics (GANX) United States $0.044B 0.00
ElectroCore (ECOR) United States $0.042B 0.00
NRx Pharmaceuticals (NRXP) United States $0.042B 0.00
Natural Alternatives (NAII) United States $0.041B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.040B 0.00
VYNE Therapeutics (VYNE) United States $0.039B 0.00
Rafael Holdings (RFL) United States $0.039B 0.00
DURECT (DRRX) United States $0.038B 0.00
Jaguar Animal Health (JAGX) United States $0.038B 0.00
Unicycive Therapeutics (UNCY) United States $0.038B 0.00
Lipocine (LPCN) United States $0.035B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.035B 0.00
Surrozen (SRZN) United States $0.034B 0.00
Viracta Therapeutics (VIRX) United States $0.030B 0.00
JanOne (JAN) United States $0.030B 0.00
BioVie (BIVI) United States $0.030B 0.00
Enlivex Therapeutics (ENLV) Israel $0.027B 0.00
Oncternal Therapeutics (ONCT) United States $0.027B 0.00
TherapeuticsMD (TXMD) United States $0.025B 0.00
Iterum Therapeutics (ITRM) Ireland $0.024B 0.00
PolyPid (PYPD) Israel $0.022B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.022B 0.00
MEI Pharma (MEIP) United States $0.021B 0.81
Indaptus Therapeutics (INDP) United States $0.021B 0.00
Aptorum Group (APM) United Kingdom $0.021B 0.00
Lyra Therapeutics (LYRA) United States $0.021B 0.00
GlycoMimetics (GLYC) United States $0.018B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.018B 0.00
Nuvilex (PMCB) United States $0.018B 0.00
Minerva Neurosciences (NERV) United States $0.017B 0.00
Talphera (TLPH) United States $0.017B 0.00
Alaunos Therapeutics (TCRT) United States $0.017B 0.00
Traws Pharma (TRAW) United States $0.016B 0.00
CERo Therapeutics Holdings (CERO) United States $0.015B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.014B 0.00
Mannatech (MTEX) United States $0.014B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.014B 0.00
Redhill Biopharma (RDHL) Israel $0.014B 0.00
Dominari Holdings (DOMH) United States $0.013B 0.00
Plus Therapeutics (PSTV) United States $0.012B 0.00
Inhibikase Therapeutics (IKT) United States $0.012B 0.00
Cosmos Health (COSM) Greece $0.012B 0.00
Mangoceuticals (MGRX) United States $0.011B 0.00
Avalo Therapeutics (AVTX) United States $0.011B 0.00
Biomerica (BMRA) United States $0.011B 0.00
TransCode Therapeutics (RNAZ) United States $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Universe Pharmaceuticals INC (UPC) China $0.009B 0.00
Molecular Templates (MTEM) United States $0.009B 0.00
SHINECO (SISI) China $0.008B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.007B 0.00
Vivos Therapeutics (VVOS) United States $0.007B 0.00
Ainos (AIMD) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Heatwurx (PCSA) United States $0.005B 0.00
XORTX Therapeutics (XRTX) Canada $0.005B 0.00
MyMD Pharmaceuticals (MYMD) United States $0.005B 0.00
Petros Pharmaceuticals (PTPI) United States $0.005B 0.00
Phio Pharmaceuticals (PHIO) United States $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
Bio-Path Holdings (BPTH) United States $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.003B 0.00
Finch Therapeutics (FNCH) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Qualigen Therapeutics (QLGN) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
China SXT Pharmaceuticals (SXTC) China $0.000B 0.00
Qilian Holding Group (QLI) China $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 5.38
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 32.86